These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25338742)

  • 41. An accelerated surface-mediated stress assay of antibody instability for developability studies.
    Kopp MRG; Wolf Pérez AM; Zucca MV; Capasso Palmiero U; Friedrichsen B; Lorenzen N; Arosio P
    MAbs; 2020; 12(1):1815995. PubMed ID: 32954930
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Five computational developability guidelines for therapeutic antibody profiling.
    Raybould MIJ; Marks C; Krawczyk K; Taddese B; Nowak J; Lewis AP; Bujotzek A; Shi J; Deane CM
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4025-4030. PubMed ID: 30765520
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment.
    Negron C; Fang J; McPherson MJ; Stine WB; McCluskey AJ
    MAbs; 2022; 14(1):2080628. PubMed ID: 35771588
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Process optimization and protein engineering mitigated manufacturing challenges of a monoclonal antibody with liquid-liquid phase separation issue by disrupting inter-molecule electrostatic interactions.
    Du Q; Damschroder M; Pabst TM; Hunter AK; Wang WK; Luo H
    MAbs; 2019; 11(4):789-802. PubMed ID: 30913985
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability.
    Bashour H; Smorodina E; Pariset M; Zhong J; Akbar R; Chernigovskaya M; Lê Quý K; Snapkow I; Rawat P; Krawczyk K; Sandve GK; Gutierrez-Marcos J; Gutierrez DN; Andersen JT; Greiff V
    Commun Biol; 2024 Jul; 7(1):922. PubMed ID: 39085379
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oxidation of therapeutic proteins and peptides: structural and biological consequences.
    Torosantucci R; Schöneich C; Jiskoot W
    Pharm Res; 2014 Mar; 31(3):541-53. PubMed ID: 24065593
    [TBL] [Abstract][Full Text] [Related]  

  • 47. N-terminal or signal peptide sequence engineering prevents truncation of human monoclonal antibody light chains.
    Gibson SJ; Bond NJ; Milne S; Lewis A; Sheriff A; Pettman G; Pradhan R; Higazi DR; Hatton D
    Biotechnol Bioeng; 2017 Sep; 114(9):1970-1977. PubMed ID: 28369727
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Therapeutic Antibody Profiler for Computational Developability Assessment.
    Raybould MIJ; Deane CM
    Methods Mol Biol; 2022; 2313():115-125. PubMed ID: 34478133
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antibody engineering to improve manufacturability.
    Wijesuriya SD; Pongo E; Tomic M; Zhang F; Garcia-Rodriquez C; Conrad F; Farr-Jones S; Marks JD; Horwitz AH
    Protein Expr Purif; 2018 Sep; 149():75-83. PubMed ID: 29655788
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quantification of in vivo site-specific Asp isomerization and Asn deamidation of mAbs in animal serum using IP-LC-MS.
    Mehl JT; Sleczka BG; Ciccimaro EF; Kozhich AT; Gilbertson DG; Vuppugalla R; Huang CS; Stevens B; Mo J; Deyanova EG; Wang Y; Huang RY; Chen G; Olah TV
    Bioanalysis; 2016 Aug; 8(15):1611-1622. PubMed ID: 27397670
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Deamidation Can Compromise Antibody Colloidal Stability and Enhance Aggregation in a pH-Dependent Manner.
    Alam ME; Barnett GV; Slaney TR; Starr CG; Das TK; Tessier PM
    Mol Pharm; 2019 May; 16(5):1939-1949. PubMed ID: 30916563
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Independent highly sensitive characterization of asparagine deamidation and aspartic acid isomerization by sheathless CZE-ESI-MS/MS.
    Gahoual R; Beck A; François YN; Leize-Wagner E
    J Mass Spectrom; 2016 Feb; 51(2):150-8. PubMed ID: 26889931
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Strategic approaches to optimizing peptide ADME properties.
    Di L
    AAPS J; 2015 Jan; 17(1):134-43. PubMed ID: 25366889
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides.
    LaFleur DW; Abramyan D; Kanakaraj P; Smith RG; Shah RR; Wang G; Yao XT; Kankanala S; Boyd E; Zaritskaya L; Nam V; Puffer BA; Buasen P; Kaithamana S; Burnette AF; Krishnamurthy R; Patel D; Roschke VV; Kiener PA; Hilbert DM; Barbas CF
    MAbs; 2013; 5(2):208-18. PubMed ID: 23575268
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improving the Developability of an Antigen Binding Fragment by Aspartate Substitutions.
    Sakhnini LI; Greisen PJ; Wiberg C; Bozoky Z; Lund S; Wolf Perez AM; Karkov HS; Huus K; Hansen JJ; Bülow L; Lorenzen N; Dainiak MB; Pedersen AK
    Biochemistry; 2019 Jun; 58(24):2750-2759. PubMed ID: 31117388
    [TBL] [Abstract][Full Text] [Related]  

  • 56. N+1 Engineering of an Aspartate Isomerization Hotspot in the Complementarity-Determining Region of a Monoclonal Antibody.
    Patel CN; Bauer SP; Davies J; Durbin JD; Shiyanova TL; Zhang K; Tang JX
    J Pharm Sci; 2016 Feb; 105(2):512-518. PubMed ID: 26869414
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A single molecular descriptor to predict solution behavior of therapeutic antibodies.
    Kingsbury JS; Saini A; Auclair SM; Fu L; Lantz MM; Halloran KT; Calero-Rubio C; Schwenger W; Airiau CY; Zhang J; Gokarn YR
    Sci Adv; 2020 Aug; 6(32):eabb0372. PubMed ID: 32923611
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Formation of disulfide bonds in proteins and peptides.
    Bulaj G
    Biotechnol Adv; 2005 Jan; 23(1):87-92. PubMed ID: 15610970
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In silico design of small peptides antagonist against leptin receptor for the treatment of obesity and its associated immune-mediated diseases.
    Munikumar M; Krishna VS; Reddy VS; Rajeswari B; Sriram D; Rao MV
    J Mol Graph Model; 2018 Jun; 82():20-36. PubMed ID: 29649778
    [TBL] [Abstract][Full Text] [Related]  

  • 60. From proof of concept to the routine use of an automated and robust multi-dimensional liquid chromatography mass spectrometry workflow applied for the charge variant characterization of therapeutic antibodies.
    Goyon A; Dai L; Chen T; Wei B; Yang F; Andersen N; Kopf R; Leiss M; Mølhøj M; Guillarme D; Stella C
    J Chromatogr A; 2020 Mar; 1615():460740. PubMed ID: 31796250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.